公开(公告)号：US20210213018A1

公开(公告)日：2021-07-15

申请号：US16332750

申请日：2017-09-12

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Gretchen SNYDER ,  Lawrence P. WENNOGLE ,  Jennifer O'BRIEN ,  Joseph HENDRICK

IPC: A61K31/519 ,  A61K45/06 ,  A61K31/4015 ,  A61P37/06 ,  A61P25/28 ,  A61P27/02

Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.

公开(公告)号：US20210338679A1

公开(公告)日：2021-11-04

申请号：US17279518

申请日：2019-09-25

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Gretchen SNYDER ,  Lawrence P. WENNOGLE ,  Jennifer O'BRIEN ,  Joseph HENDRICK

IPC: A61K31/519 ,  A61P37/06

Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

公开(公告)号：US20220072003A1

公开(公告)日：2022-03-10

申请号：US17421303

申请日：2020-01-07

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Gretchen SNYDER ,  Lawrence P. WENNOGLE ,  Jennifer O'BRIEN ,  Joseph HENDRICK ,  Robert DAVIS

IPC: A61K31/519 ,  A61P35/00

Abstract: The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.

公开(公告)号：US20160324860A1

公开(公告)日：2016-11-10

申请号：US15110640

申请日：2015-01-08

Applicant: INTRA-CELLULAR THERAPIES, INC.

Inventor： Joseph HENDRICK ,  Jennifer O'BRIEN ,  Gretchen SNYDER ,  Peng LI ,  Lawrence P. WENNOGLE

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/53

CPC classification number: A61K31/519 ,  A61K9/0048 ,  A61K31/53 ,  A61K45/06 ,  C07D487/04 ,  C07D487/14 ,  A61K2300/00

Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.

Abstract translation: 本发明涉及包含游离或盐形式的PDE1抑制剂和PDE2抑制剂的产品，其包含它们的药物组合物及其作为治疗cAMP和/或cGMP相关疾病的药物的用途。